



OPEN ACCESS

EDITED AND REVIEWED BY
Bernd Rosenkranz,
Fundisa African Academy of Medicines
Development, South Africa

*CORRESPONDENCE

Jia Li,
✉ lijia_211@hotmail.com
Yanwei Chen,
✉ chenyaweile@163.com
Deshi Dong,
✉ dongdeshi@dmu.edu.cn

RECEIVED 30 October 2024

ACCEPTED 01 November 2024

PUBLISHED 11 November 2024

CITATION

Li L, Yang S, Fang F, Tian L, He Y, Li J, Chen Y and
Dong D (2024) Corrigendum: The value of
second-line anti-HER2 therapy in metastatic
HER-2 positive patients: a cost-effectiveness
analysis in China.

Front. Pharmacol. 15:1519505.
doi: 10.3389/fphar.2024.1519505

COPYRIGHT

© 2024 Li, Yang, Fang, Tian, He, Li, Chen and
Dong. This is an open-access article distributed
under the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China

Lu Li¹, Shilei Yang¹, Fengqi Fang², Li Tian¹, Ying He¹, Jia Li^{2*},
Yanwei Chen^{1*} and Deshi Dong^{1*}

¹Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China,

²Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China

KEYWORDS

HER-2-positive metastatic breast cancer, network meta-analysis, cost-effectiveness analysis, pyrotinib plus capecitabine, T-DM1, T-DXd

A Corrigendum on

[The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China](#)

by Li L, Yang S, Fang F, Tian L, He Y, Li J, Chen Y and Dong D (2024). *Front. Pharmacol.* 15:1382120.
doi: 10.3389/fphar.2024.1382120

In the published article, there was an error. T-DXd was indicated for comparison with PC strategies instead of T-DM1.

A correction has been made to the **Abstract, Findings**. This sentence previously stated: “The PC strategies are considered more cost-effective than T-DXd when the WTP threshold is set at \$36,058.06 per QALY.”

The corrected sentence appears below:

“The PC strategies are considered more cost-effective than T-DM1 when the WTP threshold is set at \$36,058.06 per QALY.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.